Results 251 to 260 of about 402,477 (353)

Bayesian Cox Proportional Hazards Model in Survival Analysis of HACE1 Gene with Age at Onset of Alzheimer's Disease. [PDF]

Int J Clin Biostat Biom, 2017
Wang KS, Liu Y, Gong S, Xu C, Xie X, Wang L, Luo X.   +6 more
europepmc   +1 more source

Predicted survival curves for the Cox proportional hazards model [PDF]

Joanne Garrett
core  

MRI‐Derived Lymph Nodes Morphological and Topological Structure (LNs‐MTS) Model for Evaluating Immune Status and Prognosis in Rectal Cancer

Advanced Science, EarlyView.
An MRI‐derived Lymph Nodes morphological and topological structure (LNs‐MTS) model is established to evaluate the immune status of the lymph node system in rectal cancer. It provides a non‐invasive, quantitative approach for prognosis assessment and optimizing adjuvant therapy decisions.
Yunxiao Liu, Liwen Zhang, Yanfen Cui, Weiyuan Zhang, Hanqing Hu, Shuai Jiao, Jian Ma, Jiale Li, Jun Xiang, Jinna Li, Haiyi Liu, Xiaotang Yang, Jie Tian, Xishan Wang, Guiyu Wang, Xu Guan   +15 more
wiley   +1 more source

Nanos gigantium humeris insidentes: the awarded Cox proportional hazards model. [PDF]

J Thorac Dis, 2016
Bertolaccini L, Pardolesi A, Davoli F, Solli P.   +3 more
europepmc   +1 more source

Exosomal CCT6A Secreted by Cancer‐Associated Fibroblasts Interacts with β‐Catenin to Enhance Chemoresistance and Tumorigenesis in Gastric Cancer

Advanced Science, EarlyView.
Here, it is revealed that CAF‐secreted exosomal CCT6A enhances stemness, chemoresistance, and glycolysis in GC via the β‐catenin/c‐Myc/DDIT4‐TXNIP axis. Furthermore, CCT6P1, a pseudogene of CCT6A, is identified as upregulating CCT6A by competitively binding miR‐922, while c‐Myc transcriptionally activates both CCT6P1 and CCT6A.
Hui Sun, Tianqi Zhang, Xiaoyan Zhang, Yingxue Liu, Xu Wang, Xin Wang, Cong Tan, Shujuan Ni, Weiwei Weng, Meng Zhang, Lei Wang, Dan Huang, Xiaoyu Wang, Wenfeng Wang, Weiqi Sheng, Mi‐die Xu   +15 more
wiley   +1 more source

Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study

Advanced Science, EarlyView.
This study determines the maximum tolerated dose of lenvatinib in combination with paclitaxel as second‐line therapy for advanced gastric cancer patients. A dynamic network biomarker panel associated with patient prognosis and response to treatment is established.
Chenfei Zhou, Jinling Jiang, Liting Guo, Wenqi Xi, Junwei Wu, Qu Cai, Jun Ji, Feng Qi, Jun Zhang   +8 more
wiley   +1 more source

Causal Mediation Analysis for the Cox Proportional Hazards Model with a Smooth Baseline Hazard Estimator. [PDF]

J R Stat Soc Ser C Appl Stat, 2017
Wang W, Albert JM.
europepmc   +1 more source

Developing a Personalized Cancer Nanovaccine Using Coxsackievirus‐Reprogrammed Cancer Cell Membranes for Enhanced Anti‐Tumor Immunity

Advanced Science, EarlyView.
A personalized nanovaccine combining PLGA‐encapsulated heat‐inactivated CVB3 and membranes from CVB3‐infected breast cancer cells stimulates potent antitumor immunity. It reduces immunosuppressive markers, enhances immune activation, and improves survival in vivo.
Amirhossein Bahreyni, Yasir Mohamud, Amrit Singh, Razieh Sadat Banijamali, Jeffrey Tang, Jingchun Zhang, Honglin Luo   +6 more
wiley   +1 more source

Survival Analysis of COVID-19 on Democracy with Cox Proportional Hazards Model

, 2020
Zhao Y, Dilip D.
europepmc   +1 more source

Negative Outcome Control for Unobserved Confounding Under a Cox Proportional Hazards Model [PDF]

, 2015
Richardson, David, Sofer, Tamar, Tchetgen Tchetgen, Eric J   +2 more
core   +1 more source